A Physician Shaped by 30 Years of Clinical Practice — and an Honest Reckoning with What Medicine Can and Cannot Do.
Specialist Nephrologist · Physician-Scientist · Author · Medical Director · Public Speaker
Dr. Francisco Salcido-Ochoa graduated with honours from the Faculty of Medicine of the National Autonomous University of Mexico (UNAM) in Mexico City — one of Latin America's most distinguished medical institutions. Across three decades, his training and practice have taken him from London's founding teaching hospitals to specialist nephrology in Singapore.
He pursued his postgraduate training in London, obtaining his MRCP (UK) and undertaking senior medical officer postings at the Royal London Hospital and Barts Hospital. These are not peripheral institutions. They are among the founding hospitals of British medicine, and the clinical grounding acquired there — in the management of complex, undifferentiated acute disease — formed the foundation on which his subsequent specialisation was built.
He specialised in Nephrology at the Singapore General Hospital, where he spent a decade as a practising Nephrologist with a clinical subspecialty in Kidney Transplantation.
Deep specialist experience teaches something that training alone cannot. Not just the technical demands of a discipline, but its human architecture — why patients deteriorate, where interventions succeed, and where the limits of medicine become visible despite every effort.
It was this duration, and this honesty about limits, that shaped the preventive longevity philosophy that now underpins his practice.
Dr. Francisco's formation as a physician-scientist runs parallel to his clinical career, not as a detour from it.
At Imperial College London, under the supervision of Professor Sir Robert Lechler — one of the world's leading transplant immunologists — he was awarded a distinction for his MSc in thymopoiesis and received a straight pass for his PhD viva on Transplantation Tolerance and Immunoregulation.
His subsequent research at the Singapore General Hospital, supported by institutional grants, examined the immune mechanisms underlying kidney transplant rejection, glomerulonephritis, and lupus nephritis. That work produced several international publications.
More important than the publications, however, is what the research process conferred: a rigorous, methodical way of evaluating evidence — of distinguishing what is known from what is assumed, what is proven from what is plausible, and what is clinically useful from what is academically interesting.
This is the lens through which he reads the longevity literature. And it explains why his conclusions are often quieter — and more durable — than the field's loudest voices.
The interest in preventive and healthspan longevity medicine did not come from outside the clinic. It grew from within it.
Patients with chronic kidney disease rarely arrive with an isolated renal problem. They arrive with a history — years of uncontrolled hypertension, metabolic dysfunction that went unmanaged, risk factors documented in previous consultations and never seriously addressed. The disease presenting in the room is almost always the consequence of a trajectory that was visible, years earlier, to anyone looking carefully enough.
After a decade of managing the late stage, the conviction became unavoidable: the most consequential medical work happens before the crisis, not during it.
That conviction now has a structure. The practice he founded — Francisco Kidney and Medical Centre — is built around two disciplines operating together: rigorous specialist nephrology for established disease, and serious preventive longevity medicine for those whose trajectories have not yet closed.
These are not two separate services. They are one coherent clinical philosophy.
The writing of Longevity Without Illusion was not a departure from clinical practice. It was an extension of it.
The longevity conversation — loud, commercially driven, and frequently disconnected from rigorous evidence — had, in his view, developed a noise problem. Patients were navigating a landscape of competing claims with no reliable framework for evaluation. Clinicians were being asked about interventions that had outrun their evidence base. The field needed a physician willing to argue from first principles, with respect for what biology actually allows and what medicine can honestly deliver.
The book examines ageing and longevity through the lenses of physics, biology, medicine, psychology, and ethics — not as separate disciplines but as an integrated whole. It separates interventions that genuinely extend healthspan from those that merely sound convincing. And it proposes a coherent philosophy: function over duration, agency over survival, dignity over denial.
It is not a comfortable book. It was not written to be.
Learn more about the book →Medical Director and Specialist Nephrologist
Longevity Medicine and Healthspan Clinical Strategist
Francisco Kidney and Medical Centre — Singapore
Visiting Nephrologist Consultant
National Kidney Foundation — Singapore
MD (Mex) — With Honours
National Autonomous University of Mexico (UNAM)
MRCP (UK)
Royal Colleges of Physicians of the United Kingdom
MSc (UK) — Distinction
Imperial College London
Thymopoiesis
PhD (UK) — Straight Pass
Imperial College London
Transplantation Tolerance and Immunoregulation
Specialisation in Nephrology
Singapore General Hospital
Clinical Subspecialty
Kidney Transplantation
Former Institutional Research Grants
Singapore General Hospital / Duke-NUS
Kidney transplant rejection, glomerulonephritis, lupus nephritis
The work of this practice is longitudinal.
It is not organised around the management of crises — though crises are managed when they arise. It is organised around the years before the crisis, and the clinical relationship that gives those years direction.
A physician who has spent a decade watching what happens when prevention fails is a physician with a specific kind of motivation. Not urgency, exactly. Something quieter and more durable than urgency.
An understanding, earned slowly, that trajectory matters more than any single test result — and that the time to act on a trajectory is not after it has closed.
Dr. Francisco Salcido-Ochoa — MD (Mex), MRCP (UK), MSc (UK), PhD (UK)
Francisco Kidney and Medical Centre, Singapore